Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Serina Therapeutics (SER) Amortization of Deferred Charges (2019 - 2024)

Historic Amortization of Deferred Charges for Serina Therapeutics (SER) over the last 6 years, with Q4 2024 value amounting to $8000.0.

  • Serina Therapeutics' Amortization of Deferred Charges fell 9545.45% to $8000.0 in Q4 2024 from the same period last year, while for Sep 2025 it was $8000.0, marking a year-over-year decrease of 9844.05%. This contributed to the annual value of $345000.0 for FY2024, which is 3817.2% down from last year.
  • According to the latest figures from Q4 2024, Serina Therapeutics' Amortization of Deferred Charges is $8000.0, which was down 9545.45% from $8000.0 recorded in Q3 2024.
  • In the past 5 years, Serina Therapeutics' Amortization of Deferred Charges ranged from a high of $1.1 million in Q1 2023 and a low of -$1.6 million during Q3 2023
  • In the last 5 years, Serina Therapeutics' Amortization of Deferred Charges had a median value of $238500.0 in 2020 and averaged $282050.0.
  • Per our database at Business Quant, Serina Therapeutics' Amortization of Deferred Charges soared by 46808.51% in 2021 and then plummeted by 28406.47% in 2023.
  • Over the past 5 years, Serina Therapeutics' Amortization of Deferred Charges (Quarter) stood at $210000.0 in 2020, then surged by 40.0% to $294000.0 in 2021, then surged by 211.56% to $916000.0 in 2022, then plummeted by 80.79% to $176000.0 in 2023, then tumbled by 95.45% to $8000.0 in 2024.
  • Its Amortization of Deferred Charges was $8000.0 in Q4 2024, compared to $8000.0 in Q3 2024 and $166000.0 in Q2 2024.